MED · Insider Trading
Medifast, Inc.
Every open-market purchase and sale reported by MED officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-11-06 | Parsa Kiai | Director | Buy | +661 | +$8.61K |
| 2026-10-30 | Parsa Kiai | Director | Buy | +5,557 | +$68.03K |
| 2026-09-30 | Daniel R Chard | Director | Sell | −19,089 | −$226.29K |
| 2026-08-28 | Parsa Kiai | Director | Buy | +43,150 | +$529.16K |
| 2026-08-26 | Parsa Kiai | Director | Buy | +4,329 | +$51.95K |
| 2026-08-21 | Parsa Kiai | Director | Buy | +72,487 | +$842.70K |
| 2026-05-28 | Jeffrey Matthew Rose | Director | A | +18,419 | — |
| 2026-05-28 | Andrea B Thomas | Director | A | +11,680 | — |
| 2026-05-28 | Ming Xian | Director | A | +11,680 deriv. | — |
| 2026-05-28 | Elizabeth A. Geary | Director | A | +11,680 | — |
| 2026-05-28 | Scott Schlackman | Director | A | +11,680 | — |
| 2026-05-28 | Parsa Kiai | Director | A | +19,317 | — |
| 2026-05-12 | Scott Schlackman | Director | Buy | +5,000 | +$62.95K |
| 2026-03-27 | Jonathan Barrett MacKenzie | VP, Finance & CAO | MIXED | +9,700 | −$10.87K |
| 2026-03-27 | James P. Maloney | Chief Financial Officer | MIXED | +30,734 | −$44.59K |
| 2026-03-27 | Daniel R Chard | Chairman & CEO | MIXED | +29,665 | −$108.56K |
| 2025-06-26 | Scott Schlackman | Director | A | +11,168 | — |
| 2025-06-26 | Andrea B Thomas | Director | A | +11,168 | — |
| 2025-06-26 | Elizabeth A. Geary | Director | A | +11,168 | — |
| 2025-06-26 | Michael A. Hoer | Director | A | +11,168 | — |
| 2025-06-26 | Ming Xian | Director | A | +17,181 deriv. | — |
| 2025-06-26 | Jeffrey J Brown | Director | A | +20,617 | +$126.53K |
| 2025-06-17 | Daniel R Chard | Chairman & CEO | Buy | +381 | +$5.00K |
| 2025-03-27 | James P. Maloney | Chief Financial Officer | A | +24,161 | — |
| 2025-03-27 | Jonathan Barrett MacKenzie | VP, Finance & CAO | A | +7,671 | — |
| 2025-03-27 | Daniel R Chard | Chairman & CEO | A | +124,953 | — |
| 2025-03-18 | James P. Maloney | Chief Financial Officer | F | −1,396 | −$19.58K |
| 2025-03-18 | Jonathan Barrett MacKenzie | VP, Finance & CAO | F | −439 | −$6.14K |
| 2025-03-18 | Daniel R Chard | Chairman & CEO | F | −7,809 | −$109.27K |
| 2024-09-17 | Jonathan Barrett MacKenzie | VP, Finance & CAO | F | −11 | −$208 |
| 2024-06-24 | Ming Xian | Director | A | +10,149 deriv. | — |
| 2024-06-24 | Elizabeth A. Geary | Director | A | +6,596 | — |
| 2024-06-24 | Andrea B Thomas | Director | A | +6,596 | — |
| 2024-06-24 | Jeffrey J Brown | Director | A | +12,177 | +$126.47K |
| 2024-06-24 | Michael A. Hoer | Director | A | +6,596 | — |
| 2024-06-24 | Scott Schlackman | Director | A | +6,596 | — |
| 2024-03-19 | Jonathan Barrett MacKenzie | VP, Finance & CAO | F | −134 | −$4.91K |
| 2024-03-19 | James P. Maloney | Chief Financial Officer | F | −616 | −$22.55K |
| 2024-03-19 | Daniel R Chard | Chairman & CEO | F | −3,409 | −$124.80K |
| 2024-03-15 | James P. Maloney | Chief Financial Officer | A | +8,718 | — |
| 2024-03-15 | Jonathan Barrett MacKenzie | VP, Finance & CAO | A | +2,565 | — |
| 2024-03-15 | Daniel R Chard | Chairman & CEO | A | +45,087 | — |
| 2024-03-12 | Scott Schlackman | Director | MIXED | −2,753 | −$123.88K |
| 2024-02-16 | Daniel R Chard | Chairman & CEO | MIXED | +11,015 | −$288.21K |
| 2024-02-16 | James P. Maloney | Chief Financial Officer | MIXED | +1,680 | −$34.14K |
| 2023-11-09 | Jeffrey J Brown | Director | Buy | +155 | +$10.84K |
| 2023-11-09 | Andrea B Thomas | Director | Buy | +50 | +$3.47K |
| 2023-11-09 | Ming Xian | Director | Buy | +48 deriv. | — |
| 2023-11-09 | Scott Schlackman | Director | Buy | +52 | +$3.63K |
| 2023-11-09 | Michael A. Hoer | Director | Buy | +49 | +$3.43K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Daniel R Chard | Chairman & CEO | 346,064 | $4.49M |
| Jeffrey J Brown | Director | 42,810 | $555.25K |
| Scott Schlackman | Director | 42,228 | $547.71K |
| James P. Maloney | Chief Financial Officer | 40,899 | $530.46K |
| Andrea B Thomas | Director | 35,697 | $462.99K |
| Parsa Kiai | Director | 32,769 | $425.01K |
| Elizabeth A. Geary | Director | 31,225 | $404.99K |
| Michael A. Hoer | Director | 26,139 | $339.03K |
| Jeffrey Matthew Rose | Director | 18,419 | $238.89K |
| Jonathan Barrett MacKenzie | VP, Finance & CAO | 10,008 | $129.80K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the MED quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.